CVRX — CVRx, Inc.

CVRx, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $16 million, a 4% increase year-over-year.
• Full Year Revenue: $56.7 million, representing a 410% growth compared to the previous year.
• Gross Profit: $13.8 million for Q4, with a gross margin of 86%, up from 83% a year ago.
• Net Loss: $11.9 million ($0.46 per share) for 2025, compared to a net loss of $10.7 million ($0.43 per share) in 2024.
• Cash Position: $75.7 million as of December 31, 2025, with an additional $10 million borrowed in January 2026 due to a debt facility amendment.

2. Strategic Updates and Business Highlights:

• Sales Organization Transformation: Expanded to 53 territories and 252 active implanting centers, a 10% and 13% increase respectively.
• Barostim Therapy Focus: Emphasized the importance of improving quality of life for heart failure patients, with a significant market opportunity estimated at $10.5 billion, currently less than 1% penetrated.
• Category I CPT Code Transition: Effective January 1, 2026, expected to enhance patient access and reimbursement predictability.
• BENEFIT HF Trial Initiation: A landmark trial expected to triple the addressable market from 339,000 to over 980,000 patients, with enrollment anticipated to begin in 2026.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected between $63 million and $67 million, indicating growth acceleration.
• Q1 2026 Revenue Guidance: Anticipated between $13.7 million and $14.7 million.
• Gross Margin Guidance for 2026: Expected to be between 84% and 86%.
• Operating Expenses: Projected to be between $103 million and $107 million for the full year.

4. Challenges and Points of Concern:

• Net Loss Increase: The net loss widened compared to the previous year, raising concerns about profitability timelines.
• Sales Growth Rate: Q4's sequential growth in active accounts was described as low, reflecting the strategy of deepening existing accounts rather than rapid expansion.
• Integration of New Sales Reps: The integration of new representatives has had a near-term impact on growth, although long-term confidence remains.
• Market Penetration: Despite significant growth, the company remains less than 1% penetrated in its target market, indicating a long road ahead for broader adoption.

5. Notable Q&A Insights:

• BENEFIT HF Trial: The trial will include a mix of existing and new commercial sites, with expected reimbursement for devices used in the trial.
• Sales Strategy: The focus is on activating the right centers and building deeper adoption rather than just increasing the number of accounts.
• Productivity of Sales Reps: There is confidence in the productivity curve of new sales reps, with expectations of improved sales performance as they gain experience.
• Category I Code Impact: Early indications show improved approval rates for prior authorizations, suggesting a positive trend in patient access to Barostim therapy.
• Path to Profitability: Management emphasized the importance of leveraging sales growth to outpace SG&A expenses, with sufficient cash reserves to support operations through 2026.

Overall, CVRx demonstrated strong revenue growth and strategic advancements in 2025, but faces challenges in profitability and market penetration as it seeks to expand the adoption of its Barostim therapy.